Table 1.
Cardiovascular drugs with pharmacogenomic labeling (as of may 2011)
| Drug | Gene/biomarker | Label sections |
|---|---|---|
| Atorvastatin | LDLR | Warnings and precautions; clinical pharmacology; clinical studies |
| Carvedilol | CYP2D6 | Drug interactions; clinical pharmacology |
| Clopidogrel | CYP2C19 | Boxed warning; dosage and administration; warnings and precautions; drug interactions; clinical pharmacology |
| Isosorbide dinitrate/hydralazine | NAT1; NAT2 | Clinical pharmacology |
| Metoprolol | CYP2D6 | Precautions; clinical pharmacology |
| Propafenone | CYP2D6 | Clinical pharmacology |
| Propranolol | CYP2D6 | Precautions; drug interactions; clinical pharmacology |
| Warfarin | CYP2C9; VKORC1 | Dosage and administration; precautions; clinical pharmacology |